July 8, 2013

Prosensa Holding N.V. Announces Closing of Initial Public Offering

LEIDEN, the Netherlands--(BUSINESS WIRE)-- Prosensa Holding N.V. ("Prosensa") announced today the closing of its previously announced initial public offering of 6,900,000 of its ordinary shares at a price of $13.00 per share (including an additional 900,000 ordinary shares pursuant to the exercise of the over-allotment option by the underwriters). The ordinary shares began trading on the Nasdaq Global Market on June 28, 2013 under the symbol "RNA".

Prosensa intends to use the proceeds from the offering to fund its current DMD development portfolio, its early-stage DMD discovery work and DMD-support projects, to fund other non-DMD projects and for working capital and general corporate purposes.

J.P. Morgan and Citigroup acted as joint book-running managers for the offering. Leerink Swann acted as lead manager, and Wedbush PacGrow Life Sciences, KBC Securities and Trout Capital acted as co-managers.

A registration statement relating to this offering was declared effective by the Securities and Exchange Commission on June 27, 2013. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering will be made only by means of a prospectus. A copy of the preliminary prospectus relating to the offering may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717; telephone: 866-803-9204 or Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 800-831-9146, email: batprospectusdept@citi.com.

About Prosensa Holding N.V.

Prosensa is a Dutch biotechnology company engaged in the discovery and development of RNA-modulating therapeutics for the treatment of genetic disorders. Its primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy, myotonic dystrophy and Huntington's disease.

Prosensa Holding N.V.
Celia Economides, Director IR & Corporate Communications
Phone: +1 917 941 9059
Email: c.economides@prosensa.nl
or
Berndt Modig, CFO
Phone: +31-71-3322100
Email: b.modig@prosensa.nl
or
CollegeHill Life Sciences (European Media)
Sue Charles, Melanie Toyne Sewell, VeronicaSellar
Phone: +44 20 7457 2020
Email: prosensa@collegehill.com
or
Lazar Partners (US Media)
Fern Lazar, Hollister Hovey
Phone: +1 212 867 1762
Email: flazar@lazarpartners.com

Source: Prosensa Holding N.V.

News Provided by Acquire Media


Close window | Back to top

Copyright 2014 Prosensa